Israeli start-up company MeMed announced the signing of a contract with the U.S. Department of defense in the amount of $ 9.3 million.
The company, established in 2009, has developed technology to rapidly detect infections, allowing physicians to reduce time of decision-making through the necessary antibiotics and their dosages.
Under the contract MeMed will develop a second-generation blood tests to quickly determine the cause of the disease viral or bacterial.
Usually analysis on the presence of infection takes a few days, then as technology allows MeMed to get a response in a matter of hours. A new generation of analysis must give the answer within several minutes.